Contact the Editorial Desk

Editorial correspondence

Prime Peptide Labs welcomes correspondence on the research record: a citation we have quoted inaccurately, a regulatory status that has changed, or a peer-reviewed study about GHK-Cu, TB-500, or BPC-157 that belongs on the references page. Corrections that improve the accuracy of the digest are the most useful messages we receive, and they are read carefully.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That lets us verify a proposed change against the source quickly.

Editorial mailbox: editors@primepeptidelabs.com

What this desk cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Prime Peptide Labs is a literature digest, not a clinic or a vendor, so we cannot:

• Advise on, recommend, or comment on human use of any peptide discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or judge whether a research finding applies to a particular person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Provide guidance to athletes subject to anti-doping rules, given that two of the three peptides discussed are prohibited in sport.

Readers seeking medical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.